课题基金基金详情
CD98蛋白重链通过调控鞘脂合成代谢维持ALDH1阳性肺癌干细胞增殖和转移的机制分析
结题报告
批准号:
81972784
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
夏蒲
依托单位:
学科分类:
肿瘤干细胞
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
夏蒲
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
乙醛脱氢酶1(ALDH1)阳性的肺癌干细胞具有较强的致瘤性和侵袭性,是肺癌难以治愈的原因之一。CD98蛋白重链(CD98hc)在肺癌组织中高表达并调控肺癌细胞的增殖和侵袭。但是CD98hc对ALDH1阳性肺癌干细胞的作用尚不明确。我们前期研究发现肺癌组织CD98hc与ALDH1A3含量呈正相关。敲低肺腺癌细胞A549中CD98hc表达导致鞘脂合成途径重要产物1-磷酸鞘氨醇(S1P)分泌减少伴随ALDH1表达降低。而A549细胞在S1P单独作用下ALDH1活性增强。由此我们提出“CD98蛋白重链通过调控鞘脂合成代谢维持ALDH1阳性肺癌干细胞增殖和转移”这一科学命题。本项目拟检测CD98hc对ALDH1阳性肺癌干细胞增殖和侵袭的调控作用,着重分析CD98hc通过鞘脂代谢影响ALDH1阳性肺癌干细胞“干性”的机制。本项目将阐明CD98hc影响ALDH1活性的机制,为肺癌治疗提供新的分子靶点。
英文摘要
Aldehyde dehydrogenase 1 (ALDH1) positive lung cancer stem cells have strong tumorigenicity and invasiveness, which is one of the reasons why lung cancer is difficult to cure. CD98 protein heavy chain (CD98hc) is highly expressed in lung cancer tissues and regulates the proliferation and invasion of lung cancer cells. However, the effect of CD98hc on ALDH1 positive lung cancer stem cells remains unclear. Our previous studies found that there was a positive correlation between CD98hc and ALDH1A3 in lung cancer tissues. Knocking down the expression of CD98hc in lung adenocarcinoma cell line A549 resulted in a decrease of sphingosine phosphate (S1P) secretion, an important product of sphingolipid biosynthesis pathway, accompanied by a decrease of ALDH1 expression. However, the activity of ALDH1 in A549 cells increased under the action of S1P alone. Therefore, we propose the scientific proposition that CD98 protein heavy chain can maintain proliferation and metastasis of ALDH1 positive lung cancer stem cells by regulating sphingolipid metabolism. This project intends to detect the regulatory effect of CD98hc on proliferation and invasion of ALDH1 positive lung cancer stem cells, focusing on the mechanism of CD98hc affecting the stemness of ALDH1 positive lung cancer stem cells through sphingolipid metabolism. This project will elucidate the mechanism of CD98hc affecting ALDH1 activity and provide a new molecular target for lung cancer treatment.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:10.1016/j.gendis.2023.04.016
发表时间:2024-03
期刊:GENES & DISEASES
影响因子:6.8
作者:Liu, Dahua;Ren, Haolin;Wen, Guimin;Xia, Pu
通讯作者:Xia, Pu
DOI:10.3390/cancers14215191
发表时间:2022-10-22
期刊:CANCERS
影响因子:5.2
作者:Liu, Dahua;An, Min;Wen, Guimin;Xing, Yanan;Xia, Pu
通讯作者:Xia, Pu
DOI:10.1016/j.freeradbiomed.2023.07.002
发表时间:2023-07-05
期刊:FREE RADICAL BIOLOGY AND MEDICINE
影响因子:7.4
作者:Xia,Pu;Liu,Da-Hua;Zhao,Zhen-Ying
通讯作者:Zhao,Zhen-Ying
DOI:10.3389/fonc.2023.1251100
发表时间:2023
期刊:Frontiers in oncology
影响因子:4.7
作者:
通讯作者:
DOI:10.7150/ijms.79162
发表时间:2022
期刊:International journal of medical sciences
影响因子:3.6
作者:Ren HL;Wen GM;Zhao ZY;Liu DH;Xia P
通讯作者:Xia P
TGF-β选择性抑制剂研发及靶向治疗非小细胞肺癌的分子机制解析
  • 批准号:
    82211530435
  • 项目类别:
    国际(地区)合作与交流项目
  • 资助金额:
    3.00万元
  • 批准年份:
    2022
  • 负责人:
    夏蒲
  • 依托单位:
非小细胞肺癌患者血浆可溶性TRAIL对循环ALDH1+肿瘤干细胞样细胞的影响及其机制研究
  • 批准号:
    81502558
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    18.0万元
  • 批准年份:
    2015
  • 负责人:
    夏蒲
  • 依托单位:
国内基金
海外基金